{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:10:52Z","timestamp":1778217052524,"version":"3.51.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Well-differentiated neuroendocrine tumors (NETs) have a high indolent local progression rate when resistance develops to biologic or cytotoxic chemotherapy. Radiopharmaceuticals like single-agent [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]lutetium-177 dotatate confer a 17% objective NET partial response rate with prolongation of progression-free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      The patient, a 69-year-old man with gastroenteropancreatic NET with liver metastases and known chronic systolic heart failure (HF), had received octreotide then everolimus therapy prior to enrollment. At entry, his disease status was complicated by bilateral edema to his thighs worsening over a 4-week period and an echocardiogram showing right heart hypertrophic cardiomyopathy with an ejection fraction of 40%. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Gallium-68 dotatate positron emission tomography identified tumors in the lung, liver, spleen, and axial skeleton. The phase I clinical trial involved intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]lutetium-177 dotatate (day 1) given with concurrent once daily oral triapine (days 1\u201314) given as a radiosensitizer that repeated every 8 weeks for four cycles (NCT04234568); [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]lutetium-177 dotatate requires concomitant treatment with 1 L of an isotonic amino acid salt solution, usually administered over a 4-h period around the radiopharmaceutical. On cycle 1 day 8, the patient was found unresponsive at home and efforts to resuscitate him were unsuccessful. Autopsy on cycle 1 day 9 revealed acute HF in the setting of HF complicated by carcinoid heart disease, measurable radionuclide organ uptake, and widely disseminated NET with 50% tumor lysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This case reports the rare complication of an acute exacerbation of carcinoid-associated HF by the [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]lutetium-177 dotatate\u2013triapine combination. The cause of the acute cardiac decompensation could be related to the marked tumor response to treatment and\/or contributions of the renoprotective amino acid infusion.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1801126","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:43:28Z","timestamp":1778215408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of acute carcinoid heart failure during lutetium-177 dotatate\u2013triapine treatment for well-differentiated neuroendocrine tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Aman","family":"Chauhan","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise C","family":"Kohn","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute","place":["Rockville, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Percy","family":"Ivy","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute","place":["Rockville, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M","family":"Kolesar","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhi","family":"Modak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Arnold","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowell","family":"Anthony","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Carson","sequence":"additional","affiliation":[{"name":"Translational Therapeutics, The Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan R","family":"Shelman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A","family":"Kunos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2004.040329","article-title":"Carcinoid heart disease: presentation, diagnosis, and management","volume":"90","author":"Fox","year":"2004","journal-title":"Heart"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32835b7efa","article-title":"Surgical treatment of neuroendocrine tumors (including carcinoid)","volume":"20","author":"Doherty","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903328959","article-title":"From somatostatin to octreotide LAR: evolution of a somatostatin analogue","volume":"25","author":"Anthony","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61742-x","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44170","article-title":"External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy","volume":"5","author":"Das","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00572-6","article-title":"(177)Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivag001","article-title":"Transcatheter valve replacement in carcinoid heart disease: a potential change of paradigm","volume":"41","author":"Barbier","year":"2026","journal-title":"Interdiscip Cardiovasc Thorac Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1801126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:43:32Z","timestamp":1778215412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1801126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1801126"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1801126","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1801126"}}